Atara Biotherapeutics Inc (NASDAQ:ATRA) had its Outperform rating reiterated by William Blair

Analyst Ratings For Atara Biotherapeutics Inc (NASDAQ:ATRA)

Story continues below

Today, William Blair reiterated its Outperform rating on Atara Biotherapeutics Inc (NASDAQ:ATRA).

There are 6 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings, no Hold Ratings on the stock.

The current consensus rating on Atara Biotherapeutics Inc (NASDAQ:ATRA) is Buy with a consensus target price of $51.20 per share, a potential 28.81% upside.

Some recent analyst ratings include

  • 4/1/2019-Atara Biotherapeutics Inc (NASDAQ:ATRA) had its Outperform rating reiterated by William Blair
  • 2/26/2019-Atara Biotherapeutics Inc (NASDAQ:ATRA) had its Buy rating reiterated by Cowen
  • 2/26/2019-Atara Biotherapeutics Inc (NASDAQ:ATRA) had its Buy rating reiterated by Mizuho with a $62.00 price target
  • 8/3/2018-Atara Biotherapeutics Inc (NASDAQ:ATRA) had its Buy rating reiterated by Jefferies Financial Group with a $45.00 price target
  • 5/8/2018-Atara Biotherapeutics Inc (NASDAQ:ATRA) had its Buy rating reiterated by Canaccord Genuity with a $70.00 price target
  • 4/10/2018-Atara Biotherapeutics Inc (NASDAQ:ATRA) has coverage initiated with a Overweight ➝ Overweight rating and $56.00 price target
  • On 3/15/2019 Isaac E Ciechanover, CEO, sold 7,800 with an average share price of $39.48 per share and the total transaction amounting to $307,944.00.
  • On 3/15/2019 Joel S Marcus, Director, sold 20,000 with an average share price of $38.25 per share and the total transaction amounting to $765,000.00.
  • On 3/1/2019 Joe Newell, Insider, sold 1,500 with an average share price of $36.13 per share and the total transaction amounting to $54,195.00.
  • On 2/28/2019 Isaac E Ciechanover, CEO, sold 7,800 with an average share price of $36.14 per share and the total transaction amounting to $281,892.00.
  • On 2/28/2019 Joel S Marcus, Director, sold 62,590 with an average share price of $36.07 per share and the total transaction amounting to $2,257,621.30.
  • On 2/15/2019 Christopher Haqq, EVP, sold 775 with an average share price of $39.59 per share and the total transaction amounting to $30,682.25.
  • On 2/15/2019 Derrell Porter, SVP, sold 5,909 with an average share price of $40.00 per share and the total transaction amounting to $236,360.00.

About Atara Biotherapeutics Inc (NASDAQ:ATRA)
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It is also developing ATA188 and autologous ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product to treat Wilms tumor 1; and ATA230, which is Phase II clinical trials for refractory cytomegalovirus. In addition, the company is developing ATA368 that is under preclinical development for HIV and cancers. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with Moffitt Cancer Center. The company was founded in 2012 and is headquartered in South San Francisco, California.

Recent Trading Activity for Atara Biotherapeutics Inc (NASDAQ:ATRA)
Shares of Atara Biotherapeutics Inc closed the previous trading session at 39,75 up +1,11 2,87 % with 38.76 shares trading hands.

An ad to help with our costs